{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T06:37:05Z","timestamp":1776753425370,"version":"3.51.2"},"reference-count":84,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    Idiopathic Pulmonary Fibrosis (IPF) is a progressive, fatal lung disease with a median survival of 3\u20135\u202fyears, driven by a profound unmet medical need. The current standard-of-care agents, pirfenidone and nintedanib, merely slow disease progression and are burdened by significant toxicity. This review synthesizes the basic, clinical, and translational evolution of novel pharmacological approaches for IPF, analyzing the critical lessons from recent high-profile clinical trial failures and successes. This review followed a narrative, analytical methodology, examining key Phase 2 and 3 clinical trials to identify a \u201cfailure-to-refinement\u201d trajectory in drug development. Analysis reveals that targeting broad-spectrum enzymes (e.g., autotaxin via ziritaxestat) or downstream effectors (e.g., Connective Tissue Growth Factor (CTGF) via pamrevlumab) has failed, likely due to mechanistic redundancy or insufficient target engagement. In contrast, highly specific, next-generation inhibitors targeting upstream signal initiation points such as the lysophosphatidic acid receptor 1 (LPAR1) (admilparant) and local \u03b1v\n                    <jats:italic>\u03b2<\/jats:italic>\n                    6 integrin-mediated activation of transforming growth factor-beta (TGF-\u03b2) (bexotegrast) have yielded promising Phase 2 data, demonstrating a sophisticated translational learning loop. Furthermore, the geroscience approach targeting cellular senescence (dasatinib\/quercetin) has introduced a controversial new paradigm, while the recent approval of nerandomilast (a phosphodiesterase 4B (PDE4B) inhibitor) establishes a new therapeutic class. The IPF pipeline has matured, moving from broad attenuation toward specific, mechanism-based inhibition. This shift, informed by interpreting trial failures, is guiding the development of therapies toward disease modification and combination strategies, offering a tangible path toward curative-intent treatments.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2026.1748453","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T05:37:19Z","timestamp":1776749839000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond attenuation: a translational review of curative-intent pharmacological targets in idiopathic pulmonary fibrosis"],"prefix":"10.3389","volume":"13","author":[{"given":"Ghaith K.","family":"Mansour","sequence":"first","affiliation":[{"name":"Alfaisal University","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad W.","family":"Hajjar","sequence":"additional","affiliation":[{"name":"College of Medicine, Alfaisal University","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hatouf H.","family":"Sukkarieh","sequence":"additional","affiliation":[{"name":"College of Medicine, Department of Pharmacology, Alfaisal University","place":["Riyadh, Saudi Arabia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/S2213-2600(17)30433-2","article-title":"Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner society White paper","volume":"6","author":"Lynch","year":"2018","journal-title":"Lancet Respir Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1164\/ajrccm.161.2.ats3-00","article-title":"Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)","volume":"161","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"104766","DOI":"10.1016\/j.ebiom.2023.104766","article-title":"Precision medicine advances in idiopathic pulmonary fibrosis","volume":"95","author":"Karampitsakos","year":"2023","journal-title":"EBioMedicine"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.resinv.2021.04.005","article-title":"Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: a multicenter retrospective observational study in Japan","volume":"59","author":"Hisata","year":"2021","journal-title":"Respir Investig"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1183\/13993003.02316-2014","article-title":"Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review","volume":"46","author":"Raghu","year":"","journal-title":"Eur Respir J"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"26704","DOI":"10.1021\/acsnano.4c06598","article-title":"Tetrahedral framework nucleic acids delivery of Pirfenidone for anti-inflammatory and Antioxidative effects to treat idiopathic pulmonary fibrosis","volume":"18","author":"Xie","year":"2024","journal-title":"ACS Nano"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1165\/rcmb.2020-0320OC","article-title":"Kindlin-2 acts as a key mediator of lung fibroblast activation and pulmonary fibrosis progression","volume":"65","author":"Zhang","year":"","journal-title":"Am J Respir Cell Mol Biol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1273248","DOI":"10.3389\/fimmu.2023.1273248","article-title":"The role of cGAS-STING signaling in pulmonary fibrosis and its therapeutic potential","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1183\/09031936.00174914","article-title":"Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis","volume":"45","author":"Wollin","year":"2015","journal-title":"Eur Respir J"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"116282","DOI":"10.1016\/j.biopha.2024.116282","article-title":"Comprehensive review of potential drugs with anti-pulmonary fibrosis properties","volume":"173","author":"Ma","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"107329","DOI":"10.1016\/j.rmed.2023.107329","article-title":"Efficacy and safety of antifibrotic agents in the treatment of CTD-ILD and RA-ILD: a systematic review and meta-analysis","volume":"216","author":"Yang","year":"2023","journal-title":"Respir Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s00228-024-03720-7","article-title":"Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis","volume":"80","author":"Kou","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s40001-021-00601-y","article-title":"The effects and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis: a meta-analysis and systematic review","volume":"26","author":"Zang","year":"2021","journal-title":"Eur J Med Res"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e070513","DOI":"10.1136\/bmjopen-2022-070513","article-title":"Exploration of the unmet needs of patients diagnosed with idiopathic pulmonary fibrosis: a scoping review protocol","volume":"13","author":"Bramhill","year":"2023","journal-title":"BMJ Open"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e0297832","DOI":"10.1371\/journal.pone.0297832","article-title":"A scoping review of the unmet needs of patients diagnosed with idiopathic pulmonary fibrosis (IPF)","volume":"19","author":"Bramhill","year":"2024","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2102307","DOI":"10.1183\/13993003.02307-2021","article-title":"Bone morphogenetic protein 4 inhibits pulmonary fibrosis by modulating cellular senescence and mitophagy in lung fibroblasts","volume":"60","author":"Guan","year":"2022","journal-title":"Eur Respir J"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"5449","DOI":"10.1038\/s41467-024-49545-x","article-title":"Lung injury-induced activated endothelial cell states persist in aging-associated progressive fibrosis","volume":"15","author":"Raslan","year":"2024","journal-title":"Nat Commun"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1172\/JCI64098","article-title":"Cellular senescence and the senescent secretory phenotype: therapeutic opportunities","volume":"123","author":"Tchkonia","year":"2013","journal-title":"J Clin Invest"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3892\/etm.2023.11844","article-title":"Advances in cellular senescence in idiopathic pulmonary fibrosis (review)","volume":"25","author":"Han","year":"2023","journal-title":"Exp Ther Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.3390\/cells11111781","article-title":"Cellular senescence in aging lungs and diseases","volume":"11","author":"Aghali","year":"2022","journal-title":"Cells"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"101507","DOI":"10.1016\/j.arr.2021.101507","article-title":"Stress and telomere shortening: insights from cellular mechanisms","volume":"73","author":"Lin","year":"2022","journal-title":"Ageing Res Rev"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1152\/physrev.00046.2021","article-title":"Telomere-mediated lung disease","volume":"102","author":"Alder","year":"2022","journal-title":"Physiol Rev"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.3390\/cells10112892","article-title":"Pulmonary alveolar stem cell senescence, apoptosis, and differentiation by p53-dependent and -independent mechanisms in telomerase-deficient mice","volume":"10","author":"Zhang","year":"","journal-title":"Cells"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1164\/rccm.201810-1975TR","article-title":"Cellular senescence as a mechanism and target in chronic lung diseases","volume":"200","author":"Barnes","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1165\/rcmb.2022-0315OC","article-title":"Loss of ANT1 increases fibrosis and epithelial cell senescence in idiopathic pulmonary fibrosis","volume":"69","author":"Sui","year":"2023","journal-title":"Am J Respir Cell Mol Biol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e130056","DOI":"10.1172\/jci.insight.130056","article-title":"Secretion of leukotrienes by senescent lung fibroblasts promotes pulmonary fibrosis","volume":"4","author":"Wiley","year":"2019","journal-title":"JCI Insight"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1602367","DOI":"10.1183\/13993003.02367-2016","article-title":"Senolytic drugs target alveolar epithelial cell function and attenuate experimental lung fibrosis ex vivo","volume":"50","author":"Lehmann","year":"2017","journal-title":"Eur Respir J"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e173371","DOI":"10.1172\/JCI173371","article-title":"An in vivo screening platform identifies senolytic compounds that target p16INK4a+ fibroblasts in lung fibrosis","volume":"134","author":"Lee","year":"2024","journal-title":"J Clin Invest"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1506518","DOI":"10.3389\/fphar.2025.1506518","article-title":"Benzyl isothiocyanate provokes senolysis by targeting AKT in senescent IPF fibroblasts and reverses persistent pulmonary fibrosis in aged mice","volume":"16","author":"Wang","year":"2025","journal-title":"Front Pharmacol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.ebiom.2018.12.052","article-title":"Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study","volume":"40","author":"Justice","year":"2019","journal-title":"EBioMedicine"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"104481","DOI":"10.1016\/j.ebiom.2023.104481","article-title":"Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability","volume":"90","author":"Nambiar","year":"2023","journal-title":"EBioMedicine"},{"key":"ref36","first-page":"707","article-title":"Senescence of alveolar type 2 cells drives progressive pulmonary fibrosis","volume-title":"Am J Respir Crit Care Med","author":"Yao","year":"2021"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"393","DOI":"10.18632\/aging.206200","article-title":"Age-related diseases as a testbed for anti-aging therapeutics: the case of idiopathic pulmonary fibrosis","volume":"17","author":"Zhavoronkov","year":"2025","journal-title":"Aging"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1164\/rccm.202410-2018ED","article-title":"Targeting Autotaxin and lysophosphatidic acid in pulmonary fibrosis: Admilparant's positive results show continued promise","volume":"211","author":"Molyneaux","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"578282","DOI":"10.1016\/j.jneuroim.2023.578282","article-title":"Dysregulated autotaxin expression by T cells in multiple sclerosis","volume":"387","author":"Petersen-Cherubini","year":"2024","journal-title":"J Neuroimmunol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"106286","DOI":"10.1016\/j.phrs.2022.106286","article-title":"Integrated analysis of single-cell and bulk RNA sequencing reveals pro-fibrotic PLA2G7high macrophages in pulmonary fibrosis","volume":"182","author":"Wang","year":"2022","journal-title":"Pharmacol Res"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.3390\/molecules27175487","article-title":"Designing dual inhibitors of Autotaxin-LPAR GPCR Axis","volume":"27","author":"Banerjee","year":"2022","journal-title":"Molecules"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"240015","DOI":"10.1183\/16000617.0015-2024","article-title":"Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis","volume":"33","author":"Volkmann","year":"2024","journal-title":"Eur Respir Rev"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nm1685","article-title":"The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak","volume":"14","author":"Tager","year":"2008","journal-title":"Nat Med"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"3580","DOI":"10.1021\/acs.jmedchem.7b00032","article-title":"Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a first-in-class Autotaxin inhibitor undergoing clinical evaluation for the treatment of idiopathic pulmonary fibrosis","volume":"60","author":"Desroy","year":"2017","journal-title":"J Med Chem"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"e000422","DOI":"10.1136\/bmjresp-2019-000422","article-title":"Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)","volume":"6","author":"Maher","year":"2019","journal-title":"BMJ Open Respir Res"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1001\/jama.2023.5355","article-title":"Ziritaxestat, a novel Autotaxin inhibitor, and lung function in idiopathic pulmonary fibrosis: the ISABELA 1 and 2 randomized clinical trials","volume":"329","author":"Maher","year":"2023","journal-title":"JAMA"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"240260","DOI":"10.1183\/20734735.0260-2024","article-title":"\"Regression to the truth\": lessons learned from negative IPF trials","volume":"21","author":"Trachalaki","year":"2025","journal-title":"Breathe"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/cpdd.1021","article-title":"Pharmacokinetics and metabolism of Ziritaxestat (GLPG1690) in healthy male volunteers following intravenous and Oral administration","volume":"11","author":"Helmer","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.chest.2018.08.1058","article-title":"Randomized, double-blind, placebo-controlled, phase 2 trial of BMS-986020, a lysophosphatidic acid receptor antagonist for the treatment of idiopathic pulmonary fibrosis","volume":"154","author":"Palmer","year":"2018","journal-title":"Chest"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"115885","DOI":"10.1016\/j.taap.2022.115885","article-title":"Mechanism of hepatobiliary toxicity of the LPA1 antagonist BMS-986020 developed to treat idiopathic pulmonary fibrosis: contrasts with BMS-986234 and BMS-986278","volume":"438","author":"Gill","year":"2022","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1164\/rccm.202405-0977OC","article-title":"Efficacy and safety of admilparant, an LPA1 antagonist, in pulmonary fibrosis: a phase 2 randomized clinical trial","volume":"211","author":"Corte","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/MCP.0000000000001089","article-title":"Evidence from recent clinical trials in fibrotic interstitial lung diseases","volume":"30","author":"Cottin","year":"2024","journal-title":"Curr Opin Pulm Med"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.chest.2025.04.003","article-title":"Effect of Admilparant, a lysophosphatidic acid receptor 1 antagonist, on disease progression in pulmonary fibrosis","volume":"168","author":"Kreuter","year":"2025","journal-title":"Chest"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1056\/NEJM199411103311907","article-title":"Transforming growth factor beta in tissue fibrosis","volume":"331","author":"Border","year":"1994","journal-title":"N Engl J Med"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.trecan.2016.11.008","article-title":"Targeting TGF-\u03b2 signaling in cancer","volume":"3","author":"Colak","year":"2017","journal-title":"Trends Cancer"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3109\/08977194.2011.595714","article-title":"TGF-\u03b2 signaling in fibrosis","volume":"29","author":"Biernacka","year":"2011","journal-title":"Growth Factors"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"174510","DOI":"10.1016\/j.ejphar.2021.174510","article-title":"TGF-\u03b2-induced fibrosis: a review on the underlying mechanism and potential therapeutic strategies","volume":"911","author":"Ong","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1186\/1755-1536-5-S1-S24","article-title":"CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis","volume":"5","author":"Lipson","year":"2012","journal-title":"Fibrogenesis Tissue Repair"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1001\/jama.2024.8693","article-title":"Pamrevlumab for idiopathic pulmonary fibrosis: the ZEPHYRUS-1 randomized clinical trial","volume":"332","author":"Raghu","year":"2024","journal-title":"JAMA"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1136\/thoraxjnl-2021-217976","article-title":"Medical treatments for idiopathic pulmonary fibrosis: a systematic review and network meta-analysis","volume":"77","author":"Pitre","year":"2022","journal-title":"Thorax"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S2213-2600(19)30262-0","article-title":"Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"8","author":"Richeldi","year":"2020","journal-title":"Lancet Respir Med"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"685","DOI":"10.3233\/JND-230019","article-title":"Pamrevlumab, a fully human monoclonal antibody targeting connective tissue growth factor, for non-ambulatory patients with Duchenne muscular dystrophy","volume":"10","author":"Connolly","year":"2023","journal-title":"J Neuromuscul Dis"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.bbadis.2012.10.005","article-title":"Integrin-mediated regulation of TGF\u03b2 in fibrosis","volume":"1832","author":"Henderson","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/s0092-8674(00)80545-0","article-title":"The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis","volume":"96","author":"Munger","year":"1999","journal-title":"Cell"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"8662","DOI":"10.1111\/jcmm.16821","article-title":"Pirfenidone modulates macrophage polarization and ameliorates radiation-induced lung fibrosis by inhibiting the TGF-\u03b21\/Smad3 pathway","volume":"25","author":"Ying","year":"2021","journal-title":"J Cell Mol Med"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1083\/jcb.200312172","article-title":"Integrin alphaVbeta6-mediated activation of latent TGF-beta requires the latent TGF-beta binding protein-1","volume":"165","author":"Annes","year":"2004","journal-title":"J Cell Biol"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1164\/rccm.202403-0636OC","article-title":"Bexotegrast in patients with idiopathic pulmonary fibrosis: the INTEGRIS-IPF clinical trial","volume":"210","author":"Lancaster","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1056\/NEJMoa2414108","article-title":"Nerandomilast in patients with idiopathic pulmonary fibrosis","volume":"392","author":"Richeldi","year":"2025","journal-title":"N Engl J Med"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1165\/rcmb.2024-0614OC","article-title":"Insights into the cellular and molecular mechanisms behind the antifibrotic effects of Nerandomilast","volume":"73","author":"Reininger","year":"2025","journal-title":"Am J Respir Cell Mol Biol"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/S2213-2600(25)00239-5","article-title":"Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial","volume":"13","author":"Maher","year":"2025","journal-title":"Lancet Respir Med"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"A1055","DOI":"10.1164\/ajrccm-Conference.2024.209.1_MeetingAbstracts.A1055","article-title":"Buloxibutid, a novel angiotensin II type 2 receptor agonist, stabilized and improved lung function in individuals with idiopathic pulmonary fibrosis in the 36-week phase 2 AIR trial","volume":"209","author":"Ganslandt","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"2401305","DOI":"10.1183\/13993003.01305-2024","article-title":"Idiopathic pulmonary fibrosis mortality: update on trends in the modern treatment era","volume":"64","author":"Podolanczuk","year":"2024","journal-title":"Eur Respir J"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1164\/rccm.201306-1141WS","article-title":"Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report","volume":"189","author":"Blackwell","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline","volume":"192","author":"Raghu","year":"","journal-title":"Am J Respir Crit Care Med"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1517\/135437809035015393","article-title":"Pirfenidone: anti-fibrotic and cytoprotective agent as therapy for progressive kidney disease","volume":"19","author":"Cho","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"ref76","article-title":"Analysis of the safety and efficacy of different plasma concentrations of pirfenidone in patients with idiopathic pulmonary fibrosis","author":"Li","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-016-0328-5","article-title":"Pirfenidone and Nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis","author":"Lehtonen","year":"2016","journal-title":"Respir Res"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.3390\/ph17060709","article-title":"Pirfenidone and nintedanib in pulmonary fibrosis: lights and shadows","author":"Chianese","year":"2024","journal-title":"Pharmaceuticals"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.0026-2015","article-title":"Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials","author":"Noble","year":"2016","journal-title":"Eur Respir J"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2014","article-title":"Effect of pirfenidone on proliferation, TGF-beta induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts","author":"Conte","year":"2014","journal-title":"Eur J Pharm Sci"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s12890-021-01783-1","article-title":"Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis","volume":"21","author":"Finnerty","year":"2021","journal-title":"BMC Pulm Med"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"240015","DOI":"10.1183\/1600017.0015-2024","article-title":"Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis","volume":"33","author":"Bonella","year":"2024","journal-title":"Eur Respir Rev"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"4766","DOI":"10.1111\/bph.17303","article-title":"PDE4B inhibition by nerandomilast: effects on lung fibrosis and transcriptome in fibrotic rats and on biomarkers in human lung epithelial cells","volume":"181","author":"Reininger","year":"2024","journal-title":"Br J Pharmacol"},{"key":"ref84","author":"Gole","year":"2024","journal-title":"StatPearls [Internet]"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1748453\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T05:37:23Z","timestamp":1776749843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1748453\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":84,"alternative-id":["10.3389\/fmed.2026.1748453"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1748453","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"article-number":"1748453"}}